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When the IDF Diabetes Atlas was released at the
19th World Diabetes Congress, alarm bells went off
among Indian delegates as India now has 40.9 million
people with diabetes and the projected estimate for
the year 2025 was 69.9 million1.
Diabetes can now be controlled through
improved medical care, monitoring, and lifestyle
changes. The burgeoning epidemic of type 2 diabetes
mellitus is now receiving increasing attention
because of its human and fiscal costs and the
disability and death associated with the disease. The
major cause of mortality in diabetic patients is
cardiovascular disease. Indeed, non-communicable
chronic diseases including diabetes now cause a
substantial health burden in the developing world2.
These are exciting times for scientific discoveries
since the basic mechanisms of molecular pathogenesis
of diabetes are rapidly being unraveled. This, together
with the increasing sophistication of technologies and
animal models, should now permit researchers to find
newer and better therapeutic options for diabetes. This
special issue of IJMR focuses on diabetes and has a
collection of excellent articles which address the
molecular pathogenesis, genetics, biomarkers,
epidemiology and disease management, as well as
utility of model systems in diabetes research.
Hart and colleagues3 discuss the uses of health
related quality-of-life (HRQOL) assessment in
diabetes care with special reference to Type 1
diabetes and the interpretation of treatment effects
on quality of life.
The reasons for ethnic differences in the risk of
type 2 diabetes are not entirely understood. For
example, South Asians (people from India, Pakistan,
Bangladesh, Nepal and Sri Lanka) have remarkably
high prevalence of type 2 diabetes compared to
Caucasians. One important factor contributing to
increased type 2 diabetes in Asian Indians is
excessive insulin resistance (IR) compared to
Europeans4 which could be due to an environmental
or a genetic factor or by combination of both. Abate
and Chandalia5 review the status in migrant Asian
Indians and discuss how the understanding of the
etiology and mechanisms causing increased insulin
resistance in Asian Indians is expected to provide
clues to more effective prevention and treatment of
diabetes in this ethnic group.
Over the past 20 yr, extensive efforts have been
made to identify the insulin receptor signaling
pathways leading to the plasma membrane
translocation of GLUT4. McCarthy and Elmendorf6
update our current state of knowledge on the intricate
insulin signaling network responsible for glucose
transport in peripheral adipose and skeletal muscle
tissues with special reference to delineating signaling
connections spanning the insulin receptor and
GLUT4.
When ER functions are severely impaired, the
cell is eliminated by apoptosis via several apoptotic
executioners7. Explaining the protein folding
machinery and downstream signaling events,
Sundar Rajan and colleagues8 delineate how ER
stress could result in b cell dysfunction and insulin
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resistance. The concept that ‘the sustained ER stress
of obesity (or chronic overnutrition in the absence
of obesity) can get transduced into increased insulin
resistance’ is significantly important for Indians,
as we experience a total epidemiological diet
transition.
While insulin resistance and pancreatic b cell
dysfunction are the two prominent causes of type 2
diabetes, it has been proposed that both of these
complications have roots in mitochondiral defects9.
Recent findings have suggested that inherited defects
in mitochondrial oxidative phosphorylation activity
might play a key role in the development of IR.
Sreekumar and Nair10 cover this topic by providing
an integrated view on the interrelation between
skeletal muscle mitochondrial changes resulting in
reduced oxidative phosphorylation and insulin
resistance that could have potential in developing
treatments for many diseases.
Recent evidence has shown that AMPK activity
can also be regulated by physiological stimuli,
independent of the energy charge of the cell,
including hormones and nutrients. Understanding of
how to activate AMPK in skeletal muscle would offer
significant pharmacologic benefits in the treatment
of type 2 diabetes. In this context, Misra and
Chakrabarti11 explore how future targets for type 2
diabetes treatments will likely be those that can cause
beneficial changes in the activity of AMPK.
Many factors influence the rate of cellular
damage accumulation (and hence biological ageing)
and that the pathogenesis of some important diseases
is related to biological ageing. Do we have a
biomarker to monitor the accelerated biological
ageing? Recent studies propose that telomere
shortening is a marker of biological ageing and
atherosclerosis12. Balasubramanyam and colleagues13
review this exciting area of research with their recent
observation that telomere shortening in the
prediabetes state, could be an interface for
predisposition to cardiovascular disease and diabetes.
Although many of these studies were of cross-
sectional nature, a recent prospective study (West of
Scotland Primary Prevention Study) showed that the
mean leukocyte telomere length could be a predictor
of future coronary heart disease events14.
Working with cultured cell lines and an animal
model of obesity, it has been recently shown that
reactive oxygen species (ROS) have a causal role in
multiple forms of insulin resistance15. The relation
of ROS to insulin sensitivity may have evolved
because increased accumulation of ROS could be
interpreted by the cell as an imbalance between
substrate availability and oxidative capacity to which
decreased insulin signaling (and thus decreased
glucose uptake) would be an appropriate response.
Evans16 discusses the scientific rationale for
proposing the evaluation of antioxidants for insulin
resistance, and provide an update of intervention
studies, with an emphasis on clinical trials, in which
antioxidants have been tested.
Radha and Mohan17 provide an overview of the
genetic predisposition of type 2 diabetes with special
reference to Asian Indians. The opportunities are
great for future diabetes genetic epidemiology
research to provide clinically useful information,
which is the primary goal of the Human Genome
Project.
The cause of b cell destruction has remained an
enigma for years, but two discoveries in the 1970s
have provided the basis for our current thinking about
the disease18,19. The first was a strong linkage of type
1 diabetes to the highly polymorphic HLA class II
immune recognition molecules - DR and, later, DQ -
located on chromosome 6. Biomarkers that are able
to identify people at risk prior to autoantibody
appearance could be used to identify a window of
opportunity during which immunomodulation could
be more effective in preventing disease. Mehra and
colleagues20 cover this topic by reviewing the use of
genetic, immunologic, and metabolic markers to
predict type 1 diabetes.
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The review by Dejkhamron and colleagues21
provide an overview of the major advances in our
understanding of the etiology, pathogenesis, and
clinical management of Type 1 diabetes.
With the help of large-scale epidemiological
population-based studies done in India, Mohan and
colleagues22 give a first-hand information on diabetes
and its natural history starting from prediabetes stage.
The next generation of diabetes-epidemiologists need
to break away from existing models and begin to think
about ways of understanding what drives the
evolution of diabetes and other diseases in  a
population. This means we need to break away from
our orientation towards single diseases and begin to
focus on the big picture.
The modern era of the “metabolic syndrome”
began with the seminal work of Reaven in his
Banting Lecture in 1988. He described the
association of glucose intolerance, hypertension,
dyslipidaemia and obesity and termed it Syndrome
X with insulin resistance suggested as the unifying
underlying aetiological factor.  Misra and
colleagues23 give an account on metabolic syndrome
in Asian Indians. It is important to note that the
criteria for defining MS are subjected to constant
revision. Inclusion of modified cut-offs of waist
circumference and BMI and measures of truncal
subcutaneous fat in the NCEP ATPIII definition
requires further validation.
The exact mechanism(s) by which diabetes
causes retinopathy is an intense area of research and
several theories have been postulated to explain the
typical course and history of the disease. Rema and
Pradeepa24 discuss the epidemiology, pathogenesis,
current and future treatments of diabetic retinopathy
with special reference to the CURES Eye Study
which has identified several systemic risk factors for
the onset and progression of diabetic retinopathy.
Mudaliar25 provides an update of newer agents
now available and in development for the treatment
of diabetes and presents an overview of diabetes
prevention strategies. These newer agents could
change the way diabetes and its complications are
treated in the next decade.
Based on the CODI (Cost of Diabetes in India)
study, which is the most extensive and
comprehensive study done in India on cost of
treatment, Kapur26 gives a detailed cost analysis
status of diabetes care in India. It is likely that these
estimates are conservative and underestimate the true
cost of the disease.
Sridhar27 makes an attempt to explain the
interface of the diabetes and psychiatric disorders
and discuss the potential influences these disorders
and the drugs used to treat them have on each other.
An association between these disorders becomes an
extremely important area for scientific research with
therapeutic and preventive implications.
Bhonde and colleagues28 describe potential
applications of isolated islets in biological and
biomedical research. Cataloging and exploring the
function of newly identified proteins specific for the
beta cell, determining their subcellular localization,
their interaction partners, and identifying their role
in beta cell function would be a translational
‘bioengineering’ enterprise.
Srinivasan and Ramarao29 give an elaborate
overview of animal models and their applications in
diabetes research. One criticism is that animal models
of diabetes research may not have direct translational
applications in humans. However, it is important to
realize that this criticism vanishes if animal models
are used “to ask precise questions based on the
observations made in clinical practice and to research
the answers”.
We believe that this special issue provides an
efficient platform for fostering research on a range
of scientific topics and challenges and open-up
avenues for building newer and better collaborative
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partnerships between physicians, scientists and
pharmaceutical industry and health policy makers.
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